A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B)
Phase 1
Recruiting
- Conditions
- Healthy ParticipantsHemophilia AHemophilia B
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-04-05
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Equilibra Bioscience LLC
- Target Recruit Count
- 36
- Registration Number
- NCT06349473
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸California Clinical Trials Medical Group (CCTMG), Glendale, California, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
© Copyright 2025. All Rights Reserved by MedPath